| ID Source | ID |
|---|---|
| PubMed CID | 135444382 |
| CHEMBL ID | 1523019 |
| CHEBI ID | 114316 |
| SCHEMBL ID | 19385517 |
| Synonym |
|---|
| smr000135614 |
| 2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-4(1h)-pyrimidinone |
| MLS000530636 , |
| OPREA1_681074 |
| OPREA1_005944 |
| CHEBI:114316 |
| 2-[(7-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one |
| AKOS001038327 |
| AKOS005491370 |
| CCG-18454 |
| HMS2406F03 |
| AKOS005387971 |
| AC-35386 |
| 2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-1h-pyrimidin-4-one |
| bdbm67840 |
| 2-[(7-methoxy-4-methyl-quinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one |
| cid_816255 |
| CHEMBL1523019 , |
| Q27195715 |
| sr-01000464140 |
| SR-01000464140-1 |
| HY-100236 |
| madrasin |
| CS-5651 |
| madrasin, >=98% (hplc) |
| 2-((7-methoxy-4-methylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(3h)-one |
| 374913-63-0 |
| SCHEMBL19385517 |
| 2-((7-methoxy-4-methylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(1h)-one |
| BCP17484 |
| 2-(7-methoxy-4-methyl-quinazolin-2-ylamino)-5,6-dimethyl-3h-pyrimidin-4-one 2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-4(1h)-pyrimidinone (9ci) 4(1h)-pyrimidinone, 2-[(7-methoxy-4-methy |
| Z94598281 |
| EX-A2400 |
| ddd00107587 |
| bdbm50235041 |
| 2-[(7-methoxy-4-methylquinazolin-2-yl)amino]-4,5-dimethyl-1h-pyrimidin-6-one |
| C74930 |
| AS-56002 |
| ZPA91363 |
| EN300-2007606 |
| 2-[(7-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1,4-dihydropyrimidin-4-one |
| Class | Description |
|---|---|
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 9.5283 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| BRCA1 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 24.5014 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 3.7601 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.8913 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 7.9433 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| P53 | Homo sapiens (human) | Potency | 50.1187 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| IDH1 | Homo sapiens (human) | Potency | 29.0929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| beta-2 adrenergic receptor | Homo sapiens (human) | Potency | 5.6234 | 0.0058 | 6.0263 | 32.6427 | AID492947 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.7079 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 44.6684 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.2589 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 8.9125 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 65.9602 | 0.1000 | 28.9256 | 213.3130 | AID588591; AID720502 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 32.9110 | 0.0501 | 27.0736 | 89.1251 | AID588590; AID720496 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 3.9151 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 7.0795 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.5893 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 35.4813 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 31.6228 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| XBP1 | Homo sapiens (human) | IC50 (µMol) | 0.1600 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 9.7200 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | EC50 (µMol) | 20.0000 | 4.2000 | 4.2000 | 4.2000 | AID1436452 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1436452 | Inhibition of CLK mediated SF3B1 activation in human HeLa cells assessed as MDM2-pre mRNA exon skipping by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. |
| AID1436475 | Inhibition of CLK mediated SF3B1 activation in human SK-MEL-2 cells assessed as MDM2-pre mRNA exon skipping at 10 uM after 4 hrs by luciferase reporter gene assay relative to control | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||